Company profile
PULMATRIX, INC.
NASDAQ:PULMBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ITRACONAZOLE | phase2 | — | 20 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (13)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02198963 | phase1 | completed | 2014-07-01 | 2014-08-01 | Pulmatrix Inc. | 21 Day Cumulative Skin Irritation of RUT058-60 |
| NCT02671825 | phase1 | completed | 2016-01-01 | 2016-03-01 | Pulmatrix Inc. | A PK Study to Evaluate PUR0200 and a Reference Product in Healthy Subjects |
| NCT04759807 | phase1 | completed | 2021-01-04 | 2021-12-02 | Pulmatrix Inc. | A Phase 1b Study of PUR1800 in Patients With COPD |
| NCT02280395 | phase1_2 | terminated | 2014-10-01 | 2015-06-01 | Pulmatrix Inc. | A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60 |
| NCT01543191 | phase1 | completed | 2012-02-01 | 2012-12-01 | Pulmatrix Inc. | A Safety and Tolerability Study OF PUR118 In Subjects With Cystic Fibrosis |
FDA applications (0)
No records yet.